Results 51 to 60 of about 1,335,871 (234)

Long Non-Coding RNA CAR10 Facilitates Non-Small Cell Lung Cancer Cell Migration and Invasion by Modulating the miR-892a/GJB2 Pathway

Cancer Management and Research, 2021
Shanshan Li1 *,* Yize Liu2 *,* Guanzhen Qiu,2 Yinzhou Luo,2 Lan Luan,3 Tiance Xu,4 Yong Wang,2,5 Shuyue Xia1,6 1Respiratory Department, Central Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning, 110024, People’s Republic of China;
Li S, Liu Y, Qiu G, Luo Y, Luan L, Xu T, Wang Y, Xia S   +7 more
doaj  

Lysine acetyltransferase 5 in EGFR mutated non-small cell lung cancer [PDF]

, 2018
Histone modifications are crucial in activities such as transcriptional activation, gene silencing, and epigenetic cellular memory. In particular, lysine acetylation via lysine (K) acetyltransferases (KATs) has been implicated in cancer development ...
Pan, Gilbert
core  

Analysis of Efficacy and Safety of Neoadjuvant Immunochemotherapy in Patients
with Stage IB-IIIB Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer
Background and objective Neoadjuvant immunochemotherapy has emerged as an indispensable therapeutic modality for non-small cell lung cancer (NSCLC).
Zihao LI, Xin WANG, Yulong WANG, Zhuoer CUI, Xin WANG, Xiao LI, Guanchao JIANG, Xun WANG   +7 more
doaj   +1 more source

Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. [PDF]

, 2015
BackgroundKey effector(s) of mutated KRAS in lung cancer progression and metastasis are unknown. Here we investigated the role of PAK1/Crk axis in transduction of the oncogenic KRAS signal in non-small cell lung cancer (NSCLC).MethodsWe used NSCLC ...
Aljilani, Amir, Lewis, Michael, Lu, Jie, Mortazavi, Fariborz, Pezeshkpour, Gholamhossein, Phan, Ryan, Tamanoi, Fuyuhiko, Trinidad, Kenny   +7 more
core   +2 more sources

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2020
BACKGROUND Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Yi-long Wu, M. Tsuboi, Jie He, T. John, C. Grohé, M. Majem, J. Goldman, K. Laktionov, Sang-We Kim, T. Kato, H. Vu, Shun Lu, K. Lee, C. Akewanlop, Chong-Jen Yu, F. de Marinis, L. Bonanno, M. Dómine, F. Shepherd, L. Zeng, R. Hodge, A. Atasoy, Y. Rukazenkov, R. Herbst   +23 more
semanticscholar   +1 more source

Caucasian validation of downstaging from IIB to IIA in T1N1M0 patients within the 9th edition of the non‐small cell lung cancer tumor‐node‐metastasis staging

Cancer Medicine
Background The 9th edition of the lung cancer tumor‐node‐metastasis (TNM) staging introduced adjustments, including the reclassification of T1N1M0 patients from stage IIB to IIA. This update used data mostly from Asian populations.
Jingsheng Cai, Yun Li, Feng Yang
doaj   +1 more source

Inhibition of human lung cancer cell proliferation and survival by wine [PDF]

, 2014
Compounds of plant origin and food components have attracted scientific attention for use as agents for cancer prevention and treatment. Wine contains polyphenols that were shown to have anti-cancer and other health benefits.
Barron, Carly, Moore, Jesse, Pickering, Gary, Tsakiridis, Theodoros, Tsiani, Evangelia   +4 more
core   +3 more sources

Chinese Expert Consensus on Assessment and Clinical Application of 
Tertiary Lymphoid Structure for Non-small Cell Lung Cancer (2025 Version)

Chinese Journal of Lung Cancer
The tertiary lymphoid structure (TLS) plays a crucial role in the tumor microenvironment, influencing tumor development and progression. As an emerging biomarker for predicting the prognosis and treatment response in cancer patients, TLS has received ...
Lung Cancer Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association, Expert Committee on Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology   +1 more
doaj   +1 more source

Exploring a structural protein-drug interactome for new therapeutics in lung cancer [PDF]

, 2014
The pharmacology of drugs is often defined by more than one protein target. This property can be exploited to use approved drugs to uncover new targets and signaling pathways in cancer.
Bum-Erdene, Khuchtumur, Jalal, Shadia I., Li, Lang, Li, Liwei, Meroueh, Samy, Peng, Xiaodong, Pollok, Karen, Sandusky, George, Sinn, Tony, Turchi, John, Wang, Bo, Wang, Fang, Xu, David   +12 more
core   +1 more source

Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer

New England Journal of Medicine, 2018
Background Standard first‐line therapy for metastatic, squamous non–small‐cell lung cancer (NSCLC) is platinum‐based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD‐L1] expression on ≥50% of tumor cells).
L. Paz-Ares, A. Luft, D. Vicente, A. Tafreshi, M. Gümüş, J. Mazières, B. Hermes, F. Senler, T. Csőszi, A. Fülöp, J. Rodríguez-Cid, Jonathan Wilson, S. Sugawara, T. Kato, K. Lee, Ying Cheng, S. Novello, B. Halmos, Xiaodong Li, G. Lubiniecki, B. Piperdi, D. Kowalski   +21 more
semanticscholar   +1 more source